GCG and stroke disorder: Compared with the placebo group, patients treated with GLP-1 RAs showed a significant reduction in primary composite endpoint (CV death, nonfatal MI and nonfatal stroke; HR 0.90, p = 0.033), CV death (HR = 0.87, p = 0.007), and overall mortality (HR = 0.88, p = 0.002), with no significant reduction of fatal and nonfatal MI, fatal and nonfatal stroke, hospitalizations for UA or HF.